西洛他唑对糖尿病大鼠肾脏过氧化物酶体增生物激活受体γ表达的影响

目的探讨西洛他唑对高糖大鼠肾脏过氧化物酶体增生物激活受体γ(PPARγ-)表达的影响。方法雄性SD大鼠,链脲佐菌素(STZ)制备糖尿病模型。设正常对照组、糖尿病对照组及高25 mg/(kg.d)]、低18 mg/(kg.d)]剂量西洛他唑组,12周后处死动物,测血糖、糖化血红蛋白,肾重/体重,检测肾组织PPARγ-mRNA及蛋白质表达。结果与糖尿病组相比,西洛他唑无明显降低血糖作用;糖尿病对照组肾重/体重明显增加(P<0.01),西洛他唑有减轻肾肥大趋势;RT-PCR、Western blot结果显示西洛他唑能明显增强PPARγ-mRNA和蛋白质水平表达(P<0.05),高剂量组效果优于低剂量组,但无统计学差异。结论西洛他唑可能通过上调PPARγ-,对糖尿病肾脏具有保护作用。

Effects of cilostazol on peroxisome proliferators-activated receptor-γ in diabetic rat kidney

PurposeTo investigate the effect of cilostazol on peroxisome proliferators-activated receptor-γ(PPAR-γ) in diabetic rat kidney.MethodsThe diabetic model was prepared by injecting streptozocin(STZ) intraperitoneally.Male SD rats were divided into 4 groups: normal group,diabetes group,high-dose of cilostazol group(25 mg/(kg·d)] and low-dose of cilostazol group(18 mg/(kg·d)].At the end of 12th we-ek,all animals were sacrificed.The following parameters were measured: fasting blood glucose(BG),HbA1c,and the ratio of kidney weight to body weight,the level of PPAR-γ mRNA was semi-quantitated by RT-PCR and the protein expression was detected by western-blot.ResultsThe level of BG not only in low-dose cilostazol group but also in high-dose cilostazol group was not decreased significantly.There was significant increase in the ratio of kidney weight to body weight in diabetes control group compared with normal group(P<0.01),and cilostazol could reduce kidney hypertrophy.Cilostazol down-regulated the mRNA and protein levels of PPAR-γ significantly(P<0.05).ConclusionCilostazol may play a protective role on kidney by activating PPARγ,and alleviating renal injury in diabetic rats.